|
|||||
|
|

Hospitality software provider Agilysys (NASDAQ:AGYS) announced better-than-expected revenue in Q4 CY2025, with sales up 15.6% year on year to $80.39 million. The company expects the full year’s revenue to be around $318 million, close to analysts’ estimates. Its non-GAAP profit of $0.42 per share was 7.8% below analysts’ consensus estimates.
Is now the time to buy AGYS? Find out in our full research report (it’s free for active Edge members).
Agilysys’ fourth quarter results were met with a significant negative market reaction, as shares declined following the announcement. Despite exceeding Wall Street revenue expectations, management noted that non-GAAP profit came in below consensus, mainly due to higher product development and implementation costs during the holiday period. CEO Ramesh Srinivasan pointed to strong momentum in subscription-based sales, particularly across hotel, resort, and cruise ship segments, as a key growth driver. He also acknowledged that a temporary slowdown in the casino gaming business during October and November weighed on results, though this recovered in December. Srinivasan described product modernization and AI-driven implementation efficiencies as central to the company’s ability to convert bookings to revenue more rapidly.
Looking forward, Agilysys is focused on sustaining double-digit subscription revenue growth, driven by further adoption of its modernized, cloud-native hospitality software platform. Management believes that the ongoing rollout of the Marriott property management system project and increased use of AI tools will enhance both sales productivity and operational efficiency. Srinivasan noted, "We expect our profitability levels to continue increasing on a yearly basis, with major projects such as Marriott contributing to this trend." However, he cautioned that quarterly variability may persist due to the timing of large deals and continued investment in research and development to meet customer expectations for new features.
Management attributed quarterly performance to strong recurring revenue growth from subscriptions, continued progress on key hospitality projects, and improvements in project implementation speed, though higher costs and sporadic demand in certain verticals created headwinds.
Agilysys expects ongoing growth to be powered by subscription adoption, major project rollouts, and efficiency gains, while navigating potential margin headwinds and fluctuations in large-deal timing.
Looking ahead, our analysts are monitoring (1) the pace and breadth of the Marriott PMS rollout and its effect on recurring revenue, (2) continued improvement in implementation efficiency and conversion of backlog to revenue, and (3) progress in expanding the company’s international footprint and vertical diversification. The evolution of AI-enabled product enhancements and customer demand for referenceable, large-scale deployments will also be important indicators.
Agilysys currently trades at $100.08, down from $113.72 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
| Feb-12 | |
| Feb-02 | |
| Feb-01 | |
| Jan-27 | |
| Jan-27 | |
| Jan-27 | |
| Jan-27 | |
| Jan-27 | |
| Jan-26 | |
| Jan-26 | |
| Jan-26 | |
| Jan-26 | |
| Jan-26 | |
| Jan-26 | |
| Jan-26 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite